Keros Q2 FY26 net loss narrows to $28.7 million; R&D expenses drop 48.74% to $22.3 million - KROS News | RalliesKeros Q2 FY26 net loss narrows to $28.7 million; R&D expenses drop 48.74% to $22.3 million
K
KROS• Pipeline update and cash runway
- The company initiated a Phase 2 rinvatercept trial in Duchenne muscular dystrophy.
- Initial data are expected in H1 2027, and cash runway is seen into H1 2028.
Quarterly results and expense trends
- Keros Therapeutics posted a Q2 net loss of USD 28.7 million, narrowing from a USD 30.7 million loss a year earlier.
- Revenue was no revenue, versus USD 18.17 million a year earlier.
- R&D expenses fell 48.74% to USD 22.3 million, due to shifting elritercept R&D to Takeda and a 2025 restructuring.
- G&A costs dropped 40.69% to USD 8.6 million on lower professional fees and compensation tied to the restructuring.
FCX
•
